Semaglutide Tablets: What the Evidence Says About the Dose for Weight Loss

What MHRA approval and the OASIS 4 trial actually established about dosing

When the MHRA granted approval for Wegovy tablets in June 2026, it set the dose schedule based on data from the OASIS 4 phase-3 trial: 307 adults with obesity or overweight plus at least one weight-related condition, followed for 64 weeks without diabetes, alongside lifestyle changes. The result that most people ask about (roughly 13.6% average weight loss versus around 2.4% on placebo) was measured across all participants regardless of whether they stayed perfectly on schedule. Among those who followed the full titration faithfully, average loss was closer to 17%, though that figure should be read as reflecting full adherence rather than a typical outcome everyone should expect. Both figures come from the same approved medicine at the same 25 mg maintenance dose; the difference is about how consistently people were able to take it.

The titration itself is gradual by design. Starting at 1.5 mg, the body has time to adjust to the medicine's effects on gastric emptying and appetite signalling before the dose increases. Gastrointestinal effects (nausea, loose stools, indigestion) were the most commonly reported in the trial, affecting the majority of participants on the active medicine, though most described them as mild to moderate and settling over time. The broader picture of oral semaglutide dosing for weight loss covers how these phases interact with the treatment's effectiveness.

The four dose stages, and why none of them should be skipped

The schedule runs 1.5 mg, then 4 mg, then 9 mg, then 25 mg. A prescriber sets the pace; the minimum time at each stage is one month, but someone experiencing significant nausea may stay at a lower dose longer before moving up. That flexibility is built into the licensed approach. The 25 mg tablet is the maintenance dose (the level at which the trial's weight-loss data were collected) and it cannot be reached safely in the first few weeks.

One question our prescribers hear regularly is whether someone already stable on the 2.4 mg weekly Wegovy injection can move directly to the 25 mg tablet. The MHRA guidance does allow for that transition, though it still requires clinical assessment rather than a straightforward swap. Understanding the oral dose pathway explains the practical differences between injectable and tablet semaglutide in more detail. If you are reading this trying to work out whether the tablet might suit you better than a pen, that is a reasonable question, and one worth raising with a prescriber who knows your history.

It is also worth being clear about what these dose numbers are not. The 3 mg, 7 mg and 14 mg tablet strengths belong to Rybelsus, which is licensed only for type 2 diabetes. The 3 mg semaglutide tablet page explains that distinction in full. If you have come across the 7 mg semaglutide tablet and its role in weight loss, that strength is also part of the Rybelsus diabetes range rather than the Wegovy titration schedule. Mixing up the two schedules would mean either using a diabetes medicine off-label or misunderstanding the Wegovy titration, neither is safe without prescriber involvement.

How to take each dose: the absorption rules that make this medicine work

Oral semaglutide is absorbed through a co-formulation with an agent called SNAC, which requires a very specific set of conditions. The tablet must be taken first thing in the morning, before any food or drink except for a small amount of plain water, up to around 120 ml. After swallowing, nothing else by mouth for at least 30 minutes: no coffee, no tea, no breakfast, no other oral medicines. That window is not a suggestion; it is how the absorption mechanism functions. Missing or shortening it reduces the amount of medicine that reaches the bloodstream.

Unlike the weekly injection, the tablet needs no refrigeration. Room-temperature storage makes it more straightforward for travel and daily routine. Wegovy tablets covers storage and practical handling in more detail. The NHS notes the same morning routine in its patient information for semaglutide, and the MHRA approval was based on trials conducted under these conditions, so the instructions are not arbitrary. You can read the patient-level overview on the NHS semaglutide medicines page, which explains how the medicine works and what to expect at each dose stage.

What the dose schedule does not tell you, and where a prescriber comes in

The licensed schedule sets the framework; it does not decide what is right for any individual. Factors that a prescriber considers include other medicines being taken at the same time, any conditions that affect absorption or gastric motility, how previous GLP-1 treatment went if this is a switch, and whether a particular dose stage was tolerated before moving up. Dosing instructions and titration timing are decisions made with your prescriber, not from a general information page.

The cost of Wegovy tablets is a separate consideration many people want to understand before they go further. For anyone ready to have that clinical conversation, speaking to our prescribers is the straightforward next step, the consultation is free, reviewed the same day by a named GPhC-registered prescriber, and there is no obligation. The MHRA's approval of Wegovy tablets as the UK's first licensed oral GLP-1 for weight management means the evidence base now exists; whether a particular dose stage is appropriate for you is the question a prescriber is there to answer.